Dr. Liu and Dr. Wang Dr. Tianyuan Wang has been awarded a Postdoctoral and Clinical Fellowship Award by the Department of Defense's Kidney Cancer Research Program to support her study into the treatment of kidney cancer under the guidance and mentorship of Dr Li Liu. Dr. Wang will conduct research on the effectiveness of cyclopamine tartrate (CycT) in treating renal cell carcinoma (RCC) tumors. RCC is the most common type of kidney cancer and is highly vascularized, making it an attractive target for therapy. Dr. Wang's previous research has demonstrated the capability of CycT in inhibiting angiogenesis and normalizing tumor vasculature in non-small cell lung cancer (NSCLC) cells and mouse tumor models. In this newly proposed study, Dr. Wang will investigate the effects of CycT on RCC RENCA tumors in mouse model, with a focus on imaging to provide insights into the time course of drug effect and early indication of efficacy. She will also explore the potential of CycT in combination with immunotherapy to reprogram the tumor microenvironment for enhanced response. The ultimate goal is to provide new treatment options for kidney cancer patients with enhanced efficacy and decreased side-effects.